Lumenis Aims To Launch Aesthetic Photodynamic Laser By Year-End
This article was originally published in The Gray Sheet
Executive Summary
Lumenis remains on track to launch its Aluma photodynamic laser for non-ablative skin rejuvenation in the U.S. during the fourth quarter
You may also be interested in...
Lumenis Audit Finds Inappropriate Sales Recognition; External Auditor Sought
Laser developer Lumenis is searching for an independent auditing firm, following Deloitte & Touche member firm Brightman Almagor's resignation
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.